about
Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting.Transfection of fetal rat intestinal epithelial cells by viral oncogenes: establishment and characterization of the E1A-immortalized SLC-11 cell lineMeasurement of intracellular mediators in enterocytes isolated from jejunal biopsy specimens of control and cystic fibrosis patients.Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.Neuropeptides of the autonomic nervous system in Sjögren's syndrome.Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.Role of vasoactive intestinal polypeptide in the internal anal sphincter relaxation of the opossumRestoring the function of salivary glands.Alterations in nitric oxide synthase in the aged CNSVasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1.Vasoactive intestinal peptide (VIP), a putative neurotransmitter of nonadrenergic, noncholinergic (NANC) inhibitory innervation and its relevance to therapy.Protective effects of poly (butyl) cyanoacrylate nanoparticles containing vasoactive intestinal peptide against 6-hydroxydopamine-induced neurotoxicity in vitro.Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative DiseasesRegulation of the vasoactive intestinal peptide receptor.Vasoactive intestinal peptide in the lung.Biosynthesis and regulation of expression. The vasoactive intestinal peptide gene.VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment.Decreased REM sleep and altered circadian sleep regulation in mice lacking vasoactive intestinal polypeptide.A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide.High affinity vasoactive intestinal peptide receptors on fetal human nonpigmented ciliary epithelial cells.The SKW 6.4 line of human B lymphocytes specifically binds and responds to vasoactive intestinal peptide.CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. Relationship to vasoactive intestinal polypeptide.Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.Effects of calcitonin gene-related peptide (CGRP) on regional haemodynamics and on selected hepato-splanchnic arteries from the rat: a comparison with VIP and atriopeptin II.Vasoactive intestinal peptide 1-12: a ligand for the CD4 (T4)/human immunodeficiency virus receptor.Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy.Anatomical distribution of vasoactive intestinal peptide binding sites in peripheral tissues investigated by in vitro autoradiography.Shark rectal gland vasoactive intestinal peptide receptor: cloning, functional expression, and regulation of CFTR chloride channels.Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS.Four year treatment with a long acting somatostatin analogue in a patient with Verner-Morrison syndrome.The effect of stress and in vivo vasoactive intestinal peptide (VIP) treatment on the response of isolated rat aorta to norepinephrine, angiotensin II and vasopressin, and adventitial mast cells.
P2860
Q30662784-284FC9E2-7E4E-4DE2-9909-DD0A99F7DF4DQ33853015-F45FE815-CA2C-49AF-8528-16B9D15ADB15Q34394060-B7A82F89-C562-46A2-9F5F-31268363683DQ34961901-CFCC4FE9-B6FF-451C-881B-4B01282152EAQ35547045-10CFEDF1-85E5-4E7F-A1FC-8FCDDB695963Q35636782-3EB1259F-D6B7-44BD-8D1F-82BACA6C434DQ35638200-764CBF65-A524-4D39-87F7-D10954D5591BQ35811336-C0B99AF7-2CD6-4DF9-8A83-6CAD4661BD85Q37049393-14A0CFD1-E2E0-4F39-8307-122161908863Q38029328-007A00EE-3EB7-4411-A7DD-8B2263753398Q38319884-76D8FC79-D3FF-4C79-B164-DF5A3D497DD1Q38356768-11C50BDD-B352-4B8C-A191-C2DD411F1C58Q38946806-29883D5F-2A23-494B-95EB-94C1DFEE00DBQ39116758-D153B9D0-F5D1-4744-998D-7E0325F4E088Q39228836-1FBFA9C8-BBB9-4542-9045-CD462097C3A7Q39468687-E4C57590-270B-4C2A-9731-DCD47D7C685BQ39650226-165115B6-6D17-46F8-B48E-BF4516AC6E21Q40423132-26A8C541-7463-4A3A-A749-C84510994DDFQ41150452-86E63731-7DFA-4118-AAC4-BB0F6C5F0C62Q41237822-BF49DB58-08DB-49CA-B826-7F927DBEB0C9Q41477648-57EC8F47-41C2-410B-9A98-B834F24DA40BQ41554750-E7B2E164-1E4B-4A1D-B4E6-9435F9042696Q42125831-8ABEEF77-8076-4844-99DF-EED700EC3BE2Q42463768-387C5DF6-1345-429F-8CA4-2B317DBE3F76Q43450351-C8F34DCD-CEE7-4F31-814F-5799BCB1E54CQ44453410-6250D173-900F-48DE-AAF9-378668A4A388Q46848320-C26DF528-232D-4347-89E6-A6ED8E131B45Q46877549-3072536B-51E7-4889-90E6-7C74551076E0Q48521517-9A60F5B0-BBE7-4A4C-B80D-D0F710C81EA0Q48598794-352AFA5D-EC09-4F9A-9F94-32D6C929DAB6Q48668202-2492CB38-30F0-4E9D-9B24-25D2A7227657Q50505548-C7849043-0C83-4C2A-9DE5-AD271AA024BE
P2860
description
1986 nî lūn-bûn
@nan
1986 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Vasoactive intestinal peptide.
@ast
Vasoactive intestinal peptide.
@en
Vasoactive intestinal peptide.
@nl
type
label
Vasoactive intestinal peptide.
@ast
Vasoactive intestinal peptide.
@en
Vasoactive intestinal peptide.
@nl
prefLabel
Vasoactive intestinal peptide.
@ast
Vasoactive intestinal peptide.
@en
Vasoactive intestinal peptide.
@nl
P356
P1476
Vasoactive intestinal peptide.
@en
P2093
P2888
P304
P356
10.1007/BF03348097
P577
1986-04-01T00:00:00Z
P6179
1052154289